The Relationship Between Carotid Intima Media Thickness, Inflammation and GLA Rich Protein Levels in Chronic Kidney Disease

References

• Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(12):672–681. doi:10.1038/ncpneph0954
   PubMedGoogle Scholar
• Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;57(05):327–335. doi:10.5414/CNP57327
   PubMedGoogle Scholar
• Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20(7):1453–1464. doi:10.1681/ASN.2008070692
   PubMed Web of Science ®Google Scholar
• Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol. 1993;143(4):1003–1008.
   PubMed Web of Science ®Google Scholar
• Dhore CR, Cleutjens JPM, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21(12):1998–2003. doi:10.1161/hq1201.100229
   PubMed Web of Science ®Google Scholar
• Viegas CSB, Rafael MS, Enriquez JL, et al. Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. Arterioscler Thromb Vasc Biol. 2015;35(2):399–408. doi:10.1161/ATVBAHA.114.304823
   PubMed Web of Science ®Google Scholar
• Cavaco S, Viegas CSB, Rafael MS, et al. Gla-rich protein is involved in the cross-talk between calcification and inflammation in osteoarthritis. Cell Mol Life Sci. 2016;73(5):1051–1065. doi:10.1007/s00018-015-2033-9
   PubMed Web of Science ®Google Scholar
• Viegas CSB, Costa RM, Santos L, et al. Gla-rich protein function as an anti-inflammatory agent in monocytes/macrophages: implications for calcification-related chronic inflammatory diseases. PLoS One. 2017;12(5):1–23. doi:10.1371/journal.pone.0177829
   Web of Science ®Google Scholar
• Viegas CSB, Santos L, Macedo AL, et al. Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification: a role for GRP (Gla-Rich Protein). Arterioscler Thromb Vasc Biol. 2018;38(3):575–587. doi:10.1161/ATVBAHA.117.310578
   PubMed Web of Science ®Google Scholar
• Silva AP, Viegas CSB, Mendes F, et al. Gla-Rich Protein (GRP) as an early and novel marker of vascular calcification and kidney dysfunction in diabetic patients with CKD: a Pilot Cross-Sectional Study. J Clin Med. 2020;9(3):635. doi:10.3390/jcm9030635
   PubMed Web of Science ®Google Scholar
• Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil lymphocyte ratio and cardiovascular disease risk: a Systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:1–11. doi:10.1155/2018/2703518
   Web of Science ®Google Scholar
• Okyay GU, Inal S, Öneç K, et al. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail. 2013;35(1):29–36. doi:10.3109/0886022X.2012.734429
   PubMed Web of Science ®Google Scholar
• Yoshitomi R, Nakayama M, Sakoh T, et al. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238–243. doi:10.1080/0886022X.2019.1595645
   PubMed Web of Science ®Google Scholar
• Ye GL, Chen Q, Chen X, et al. The prognostic role of platelet-to-lymphocyte ratio in patients with acute heart failure: a cohort study. Sci Rep. 2019;9(1):1–8. doi:10.1038/s41598-019-47143-2
   PubMed Web of Science ®Google Scholar
• Yüksel M, Yıldız A, Oylumlu M, et al. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol. 2015;15(8):640–647. doi:10.5152/akd.2014.5565
   PubMed Web of Science ®Google Scholar
• Kim JK, Song YR, Kim MG, Kim HJ, Kim SG. Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovasc Disord. 2013;13(1):1–10. doi:10.1186/1471-2261-13-96
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Kasiske BL, Abboud O, et al. Foreword. Kidney Int. 2009;76(SUPPL. 113):S1–S130. doi:10.1038/ki.2009.188
   Web of Science ®Google Scholar
• Simova I, Katova T, Denchev S. Diagnostic accuracy of flow-mediated dilatation and intima-media thickness for the presence of significant coronary artery disease. J Am Soc Hypertens. 2009;3(6):388–394. doi:10.1016/J.JASH.2009.09.003
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659. doi:10.1001/archinte.164.6.659
   PubMed Web of Science ®Google Scholar
• Geroulakos G, O’Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J. 1994;15(6):781–785. doi:10.1093/oxfordjournals.eurheartj.a060585
   PubMed Web of Science ®Google Scholar
• Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048–1056. doi:10.1093/ndt/gfh813
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke. 2000;31(10):2426–2430. doi:10.1161/01.STR.31.10.2426
   PubMed Web of Science ®Google Scholar
• Makita S, Abiko A, Naganuma Y, Nagai M, Nakamura M. Chronic kidney disease is associated with increased carotid artery stiffness without morphological changes in participants of health check-up programs. Atherosclerosis. 2010;213(1):306–310. doi:10.1016/j.atherosclerosis.2010.08.057
   PubMed Web of Science ®Google Scholar
• Suliman ME, García-López E, Anderstam B, Lindholm B, Stenvinkel P. Chapter 6 Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on Fetuin-A in chronic kidney disease. Adv Clin Chem. 2008;46:217–262. doi:10.1016/S0065-2423(08)00406-X
   PubMed Web of Science ®Google Scholar
• Ketteler M, Westenfeld R, Schlieper G, Brandenburg V. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol. 2005;9(4):265–270. doi:10.1007/s10157-005-0385-4
   PubMedGoogle Scholar
• London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14(suppl 4):S305–S309. doi:10.1097/01.asn.0000081664.65772.eb
   PubMed Web of Science ®Google Scholar
• Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998;18(3):379–388. doi:10.1161/01.ATV.18.3.379
   PubMed Web of Science ®Google Scholar
• Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas heart study. J Am Soc Nephrol. 2005;16(2):507–513. doi:10.1681/ASN.2004070610
   PubMed Web of Science ®Google Scholar
• Derici U, El Nahas AM. Vascular calcifications in uremia: old concepts and new insights. Semin Dial. 2006;19(1):60–68. doi:10.1111/j.1525-139X.2006.00120.x
   PubMed Web of Science ®Google Scholar
• Dellegrottaglie S, Sanz J, Rajagopalan S. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med. 2006;6(5):515–524. doi:10.2174/156652406778018653
   PubMed Web of Science ®Google Scholar